MINNEAPOLIS, Nov. 12 /PRNewswire/ -- Urologix, Inc. (Nasdaq: ULGX)
announced today the public offering of 1,500,000 shares of common stock at a
price of $19.625 per share through an underwriting syndicate headed by
BT Alex. Brown Incorporated, Dain Bosworth Incorporated and PaineWebber
Incorporated.  All of the shares are being offered by the company.  Upon
completion of the offering, the company will have 10,841,696 shares of common
stock outstanding.  The company has granted the underwriters an option to
purchase an additional 225,000 shares to cover over-allotments, if any.
    The company intends to use the proceeds from the offering to fund sales
and marketing expenditures, to expand manufacturing capacity, and for working
capital and other general corporate purposes.
    Urologix, Inc., based in Minneapolis, develops, manufactures and markets
minimally invasive medical devices for the treatment of urological diseases.
The company has developed the Targis System(TM), a non-surgical,
anesthesia-free, catheter-based therapy that uses a proprietary microwave
technology for the treatment of benign prostatic hyperplasia (BPH), a disease
that affects over 23 million men worldwide.  The Targis System has been
approved for marketing in the United States, the European Union, Japan and
Canada.  The stock trades on the Nasdaq Stock Market under the symbol "ULGX."

Link to this page: